Exelixis, Inc. (NASDAQ:EXEL)‘s stock had its “hold” rating reissued by analysts at Stifel Nicolaus in a note issued to investors on Thursday, September 7th. They presently have a $26.00 price objective on the biotechnology company’s stock. Stifel Nicolaus’ price objective points to a potential downside of 5.69% from the company’s current price.
Several other research analysts also recently commented on EXEL. TheStreet upgraded Exelixis from a “c” rating to a “b-” rating in a research note on Monday, August 7th. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Thursday, July 27th. Cowen and Company reiterated an “outperform” rating on shares of Exelixis in a research note on Thursday, August 10th. BidaskClub downgraded Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 14th. Finally, Oppenheimer Holdings, Inc. initiated coverage on Exelixis in a research note on Monday, June 12th. They set a “hold” rating for the company. Five investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $26.51.
Exelixis (NASDAQ:EXEL) traded up 1.21% during mid-day trading on Thursday, reaching $27.57. The company’s stock had a trading volume of 8,048,436 shares. The stock has a market cap of $8.10 billion, a P/E ratio of 139.24 and a beta of 1.97. The firm’s 50 day moving average is $27.06 and its 200-day moving average is $23.39. Exelixis has a one year low of $10.04 and a one year high of $29.50.
Exelixis (NASDAQ:EXEL) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.02. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The company had revenue of $99.01 million during the quarter, compared to the consensus estimate of $85.27 million. During the same period in the previous year, the company posted ($0.15) EPS. The firm’s revenue for the quarter was up 173.1% compared to the same quarter last year. Equities analysts expect that Exelixis will post $0.27 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.truebluetribune.com/2017/09/17/exelixis-exel-hold-rating-reiterated-at-stifel-nicolaus.html.
In other Exelixis news, CFO Christopher J. Senner sold 100,000 shares of Exelixis stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $26.79, for a total value of $2,679,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Patrick J. Haley sold 60,640 shares of Exelixis stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $27.21, for a total value of $1,650,014.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 560,640 shares of company stock valued at $15,087,014. 5.10% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its holdings in Exelixis by 33,678.5% in the 1st quarter. BlackRock Inc. now owns 19,155,466 shares of the biotechnology company’s stock valued at $415,099,000 after acquiring an additional 19,098,757 shares in the last quarter. Prudential Financial Inc. raised its holdings in Exelixis by 262.0% in the 2nd quarter. Prudential Financial Inc. now owns 627,530 shares of the biotechnology company’s stock valued at $15,456,000 after acquiring an additional 454,197 shares in the last quarter. GAM Holding AG acquired a new position in Exelixis in the 2nd quarter valued at $1,256,000. Swiss National Bank raised its holdings in Exelixis by 18.4% in the 1st quarter. Swiss National Bank now owns 448,400 shares of the biotechnology company’s stock valued at $9,717,000 after acquiring an additional 69,700 shares in the last quarter. Finally, Credit Suisse AG raised its holdings in Exelixis by 20.1% in the 1st quarter. Credit Suisse AG now owns 768,110 shares of the biotechnology company’s stock valued at $16,646,000 after acquiring an additional 128,398 shares in the last quarter. 79.20% of the stock is owned by hedge funds and other institutional investors.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.